Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BUR BATS:IGV NASDAQ:SLS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBURBurford Capital$4.22+0.1%$4.61$3.59▼$15.10$922.28M1.232.48 million shs1.77 million shsIGViShares Expanded Tech-Software Sector ETF$90.92-0.7%$88.89$73.93▼$117.99$10.14B1.1522.31 million shs20.56 million shsSLSSELLAS Life Sciences Group$7.75+8.4%$6.22$1.39▼$9.51$1.41B2.510.52 million shs6.25 million shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBURBurford Capital-5.19%-2.32%-11.57%-45.92%-67.99%IGViShares Expanded Tech-Software Sector ETF-1.47%-8.60%+0.98%+7.75%-13.52%SLSSELLAS Life Sciences Group-6.90%-12.70%+36.19%+42.15%+364.29%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBURBurford Capital$4.22+0.1%$4.61$3.59▼$15.10$922.28M1.232.48 million shs1.77 million shsIGViShares Expanded Tech-Software Sector ETF$90.92-0.7%$88.89$73.93▼$117.99$10.14B1.1522.31 million shs20.56 million shsSLSSELLAS Life Sciences Group$7.75+8.4%$6.22$1.39▼$9.51$1.41B2.510.52 million shs6.25 million shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBURBurford Capital-5.19%-2.32%-11.57%-45.92%-67.99%IGViShares Expanded Tech-Software Sector ETF-1.47%-8.60%+0.98%+7.75%-13.52%SLSSELLAS Life Sciences Group-6.90%-12.70%+36.19%+42.15%+364.29%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBURBurford Capital 2.17Hold$9.33121.43% UpsideIGViShares Expanded Tech-Software Sector ETF 2.69Moderate Buy$90.92N/ASLSSELLAS Life Sciences Group 2.00Hold$10.0029.03% UpsideCurrent Analyst Ratings BreakdownLatest IGV, BUR, SLS, and TRG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2026BURBurford Capital B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/11/2026BURBurford Capital Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D+) ➝ Sell (D-)5/11/2026BURBurford Capital Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$5.005/11/2026BURBurford Capital WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$4.75 ➝ $5.005/8/2026BURBurford Capital Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold4/21/2026SLSSELLAS Life Sciences Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/30/2026BURBurford Capital WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform ➝ Neutral$6.00 ➝ $4.753/27/2026BURBurford Capital Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)3/27/2026BURBurford Capital WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$13.00 ➝ $6.003/12/2026SLSSELLAS Life Sciences Group Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$7.00 ➝ $10.00(Data available from 6/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBURBurford Capital$413.36M2.23$0.29 per share14.73$14.29 per share0.29IGViShares Expanded Tech-Software Sector ETFN/AN/AN/AN/AN/AN/ASLSSELLAS Life Sciences GroupN/AN/AN/AN/A$0.46 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBURBurford Capital$62.57M-$7.33N/A4.960.0515.14%11.72%5.42%8/6/2026 (Estimated)IGViShares Expanded Tech-Software Sector ETFN/AN/A45.14N/AN/AN/AN/AN/AN/ASLSSELLAS Life Sciences Group-$26.86M-$0.23N/AN/AN/AN/A-47.12%-42.63%8/11/2026 (Estimated)Latest IGV, BUR, SLS, and TRG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026SLSSELLAS Life Sciences Group-$0.06-$0.05+$0.01-$0.05N/AN/A3/19/2026Q4 2025SLSSELLAS Life Sciences Group-$0.0633-$0.05+$0.0133-$0.05N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBURBurford Capital$0.122.92%N/AN/A N/AIGViShares Expanded Tech-Software Sector ETFN/A0.45%N/AN/AN/ASLSSELLAS Life Sciences GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBURBurford Capital1.5913.7213.72IGViShares Expanded Tech-Software Sector ETFN/AN/AN/ASLSSELLAS Life Sciences GroupN/A17.2217.22Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBURBurford CapitalN/AIGViShares Expanded Tech-Software Sector ETFN/ASLSSELLAS Life Sciences Group17.38%Insider OwnershipCompanyInsider OwnershipBURBurford Capital8.91%IGViShares Expanded Tech-Software Sector ETFN/ASLSSELLAS Life Sciences Group1.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBURBurford Capital140219.07 million199.55 millionNot OptionableIGViShares Expanded Tech-Software Sector ETFN/A111.55 millionN/ANot OptionableSLSSELLAS Life Sciences Group10196.63 million194.08 millionNot OptionableIGV, BUR, SLS, and TRG HeadlinesRecent News About These CompaniesSLS Stock Slides Premarket: Traders Brace For Key Arbitration Ruling In GPS China Payment DisputeJune 5, 2026 | finance.yahoo.comAnalyzing SELLAS Life Sciences Group (NASDAQ:SLS) and Exelixis (NASDAQ:EXEL)June 4, 2026 | americanbankingnews.comSELLAS Life Sciences boosts liquidity through warrant exercisesJune 2, 2026 | tipranks.comJim Cramer on SELLAS: “It’s a Great Spec”June 1, 2026 | insidermonkey.comSELLAS Life Sciences Group (SLS) Is Up 21.4% After REGAL Nears Topline Readout And Cramer EndorsementMay 30, 2026 | finance.yahoo.comSLS Stock Extends Rally Overnight: CEO Says ‘Bullish’ Leukemia Data Could Drive NCCN Recognition For GPSMay 28, 2026 | finance.yahoo.comSellas Life Sciences: The Internal Inconsistency Of An Assumed Positive REGAL ReadoutMay 28, 2026 | seekingalpha.comSLS stock surges toward fifth weekly rise: CEO touts GPS as lifeline for elderly patients as cancer summit loomsMay 27, 2026 | msn.comSLS Stock Heads For Its Best Month This Year Ahead Of Key AML Trial ReadoutMay 26, 2026 | finance.yahoo.comSLS stock heads for their best month this year ahead of key AML trial readoutMay 26, 2026 | msn.comSellas Life Sciences: REGAL Delay May Be A Warning Sign, Not A Bullish SignalMay 22, 2026 | seekingalpha.comSLS stock jumps premarket: CEO says GPS AML data has ‘very good chance’ to beat earlier survival outcomesMay 20, 2026 | msn.comSELLAS Life Sciences Stock Is Surging Wednesday: What's Driving The Move?May 20, 2026 | benzinga.comSELLAS Life Sciences Stock Is Surging Wednesday: What's Driving The Move?May 20, 2026 | benzinga.comSLS stock rallies after hours as CEO teases leukemia study data any day nowMay 19, 2026 | msn.comSELLAS Life Sciences (SLS) Is Up 50.5% After Pivotal AML Trial Nears Readout And Adds Funding Flexibility – Has The Bull Case Changed?May 16, 2026 | uk.finance.yahoo.comSLS stock hits 4-year high: BlackRock stake boost fuels buzz around looming AML trial readoutMay 14, 2026 | msn.comSELLAS Life Sciences to Participate in Upcoming Investor ConferencesMay 14, 2026 | globenewswire.comSLS on track to clock best week in over 4 months: Retail divided between stock drop or multibagger status amid upcoming leukemia trial readoutMay 13, 2026 | msn.comSELLAS rises as Q1 update suggests lead program nears final analysisMay 13, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesDatavault Gains Traction: 5 Reasons to Sell NowBy Thomas Hughes | May 15, 2026RTX Is Set to Revolutionize Munitions ManufacturingBy Jeffrey Neal Johnson | May 28, 2026Ross Stores Earnings Beat Sends Stock To New HighsBy Jennifer Ryan Woods | May 25, 20263 Energy Stocks Built for the AI Power Boom—And BeyondBy Bridget Bennett | June 8, 2026Uranium Energy Corp Melts Down—Nuclear Opportunity at HandBy Thomas Hughes | June 10, 2026IGV, BUR, SLS, and TRG Company DescriptionsBurford Capital NYSE:BUR$4.22 +0.01 (+0.12%) Closing price 03:59 PM EasternExtended Trading$4.26 +0.04 (+0.95%) As of 06:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Burford Capital Limited provides legal finance products and services worldwide. The company operates through two segments, Capital Provision, and Asset Management and Other Provision. The Capital Provision segment provides capital to the legal industry or in connection with legal matters directly and through investment in private funds; legal risk management services; lower risk legal finance business focusing on pre-settlement litigation matters with lower risk and lower expected returns; post-settlement finance; and complex strategies in which it acts as a principal and acquires assets that are mispriced. The Asset Management and Other Services segment provides services to the legal industry, including litigation insurance. Burford Capital Limited was incorporated in 2009 and is based in Saint Peter Port, Guernsey.iShares Expanded Tech-Software Sector ETF BATS:IGV$90.92 -0.66 (-0.72%) As of 04:10 PM EasterniShares North American Tech-Software ETF (the Fund), formerly iShares S&P North American Technology-Software Index Fund, is an exchange-traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the S&P North American Technology Software Index (the Underlying Index). The Underlying Index measures the performance of United States-traded stocks of software-related companies in the United States and Canada. The Underlying Index includes companies that are producers of client/server applications, enterprise software, application software, personal computers and home entertainment software. The Fund’s investment advisor is BlackRock Fund Advisors.SELLAS Life Sciences Group NASDAQ:SLS$7.75 +0.60 (+8.39%) Closing price 04:00 PM EasternExtended Trading$7.76 +0.01 (+0.19%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Microsoft Just Gave Investors 3 Dates They Can't Afford to Ignore SpaceX IPO Fears Are Overblown, But the AI Bet Is Real The Biggest Opportunity From SpaceX’s IPO May Surprise You NVIDIA’s Outlook Gains Momentum: Stock Price to Follow Chewy’s Growth Engine Is Stronger Than the Market Thinks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
